Form 13-F position report

GINKGO BIOWORKS HOLDINGS INC C

Reported by STATE STREET CORPORATION

DNA CUSIP 37611X100 Manager CIK 0000093751

Reported 12,411,855 shares, up 8,411,787 (210.3%) from the prior quarter.

Reported value 83.3%; share count 210.3% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q2 2022
Shares 12,411,855 Quarter-end amount reported
Reported value $29,540,000 Fair value at quarter end
Consecutive quarters held 3 Through Q2 2022

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 31559000
2022-03-31 16120000
2022-06-30 29540000
2022-09-30 41155000
2022-12-31 23502029
2023-03-31 19560109
2023-06-30 38471779
2023-09-30 40641262
2023-12-31 44030662
2024-03-31 30839173
2024-06-30 3373978
2024-09-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

12 quarters
Quarterly reported position history for GINKGO BIOWORKS HOLDINGS INC C held by STATE STREET CORPORATION.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2024 Reduced 0 -10,092,665 (-100.0%) 0 $0 2024-11-14
Q2 2024 Reduced 10,092,665 -16,492,829 (-62.0%) < 0.01% $3,373,978 2024-08-14
Q1 2024 Added 26,585,494 +531,848 (2.0%) < 0.01% $30,839,173 2024-05-15
Q4 2023 Added 26,053,646 +3,599,910 (16.0%) < 0.01% $44,030,662 2024-02-14
Q3 2023 Added 22,453,736 +1,769,984 (8.6%) < 0.01% $40,641,262 2023-11-14
Q2 2023 Added 20,683,752 +5,976,244 (40.6%) < 0.01% $38,471,779 2023-08-14
Q1 2023 Added 14,707,508 +800,982 (5.8%) < 0.01% $19,560,109 2023-05-15
Q4 2022 Added 13,906,526 +715,840 (5.4%) < 0.01% $23,502,029 2023-02-14
Q3 2022 Added 13,190,686 +778,831 (6.3%) < 0.01% $41,155,000 2022-11-15
Q2 2022 Added 12,411,855 +8,411,787 (210.3%) < 0.01% $29,540,000 2022-08-15
Q1 2022 Added 4,000,068 +202,403 (5.3%) < 0.01% $16,120,000 2022-05-16
Q4 2021 New 3,797,665 +3,797,665 (0.0%) < 0.01% $31,559,000 2022-02-14

Who else reported the position

278 managers reported GINKGO BIOWORKS HOLDINGS INC C for Q2 2022.

Managers reporting GINKGO BIOWORKS HOLDINGS INC C in Q2 2022.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BAILLIE GIFFORD & CO Added 205,327,786 +37,575,106 0.5% $488,680,000 4 qtrs
ARK Investment Management LLC Added 87,358,057 +22,824,417 1.59% $269,063,000 4 qtrs
VANGUARD GROUP INC Added 86,735,032 +57,401,650 < 0.01% $206,429,000 3 qtrs
GENERAL ATLANTIC L P Reduced 69,435,733 -21,375,081 2.16% $165,257,000 4 qtrs
Anchorage Capital Group L L C Unchanged 69,158,354 0 16.46% $164,597,000 4 qtrs
MORGAN STANLEY Added 39,213,029 +14,233,562 0.01% $93,329,000 4 qtrs
BlackRock Inc Added 32,353,263 +16,399,997 < 0.01% $77,001,000 3 qtrs
VIKING GLOBAL INVESTORS LP Reduced 27,084,126 -23,971,018 0.29% $64,460,000 4 qtrs
Nikko Asset Management Americas Inc Added 21,858,173 +6,937,185 0.65% $52,678,000 4 qtrs
Sumitomo Mitsui Trust Holdings Inc New 21,858,173 +21,858,173 0.04% $52,022,000 4 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2022
Filed
August 15, 2022
Filing type
13F-HR
Position type
CL A SHS

Voting authority reported

Sole
11,299,390
Shared
23,300
None
1,089,165

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.